News Corporate

Werfen increases sales by over 13% and reaffirms its global leadership in in vitro diagnostics

Barcelona - April 26, 2018

Werfen, a global leader in healthcare and life sciences, achieves revenues of 1,337 million euros in 2017, a 13.3% increase against 2016.

Excluding the impact of recent acquisitions, sales from organic growth grew by 4.6%. With these results, Werfen continues to be a global leader in in vitro diagnostics, providing innovative solutions for hospitals and commercial laboratories with the aim of improving patient care and reducing healthcare costs.

Werfen is reporting net profit of 160 million euros for 2017, representing a 15.1% increase over 2016. EBITDA has grown to 284 million euros, representing an increase of 6%.

Werfen is performing very well in its main areas of expertise. Hemostasis has an increase of 7.5%, Autoimmunity has grown by 6.6%, while the new business line, Acute Care Diagnostics, has achieved organic growth of 4.8%.

The expansion of the product portfolio has been one of the main causes of the increase in sales following the acquisitions of Tem and Accriva Diagnostics. As a result, the Critical Care business line has evolved into Acute Care Diagnostics, providing comprehensive solutions for emergency care, traumatology, and operating rooms.

Werfen has strengthened its presence in all regions, especially in China, where sales have achieved a 21% increase against 2016. Currently, Asia-Pacific accounts for 16% of total revenues.

Western Europe is the strongest market, bringing in 42% of Werfen revenues, while North America accounted for 26%. The areas with the greatest potential for growth are Latin America and EEMEAI (Eastern Europe, Middle East, Africa and India), each of which generated 8% of total sales.

The objectives set for 2018 are to further strengthen the main areas of expertise, to continue to grow in China, and to boost expansion in the emerging markets of Latin America, Asia-Pacific and EEMEAI.

 

WERFEN is one of the leading global corporations in IVD through its companies Instrumentation Laboratory (Hemostasis, Acute Care Diagnostics), Inova Diagnostics (Autoimmunity) and Biokit (OEM, infectious disease serology); in addition to clinical software and chemical chemistry. Werfen is also involved in medical devices through its company Leventon and other entities for distribution.

Werfen has a direct presence in around 30 countries and more than 100 territories through distributors. It has a team of over 5,000 people, and its R&D and manufacturing activities are carried out in the United States and Europe.

Share Press Release:

LinkedIn twitter

Contact Us


Contact us directly filling out the form below.

Tel +61 2 9098 0200

Consenso
DATA PROTECTION POLICY: In application of the Personal Data Protection regulations, we inform that your personal data will be incorporated and processed in a file under the responsibility of WERFEN for the purpose of maintaining the commercial relationship (order management and / or billing, sending product notices, managing business relationships, including conducting surveys, prospecting, statistical analysis and other activities related to the management of business visits), as well as to provide by any means (electronic or not), information about our products and / or services that may be of interest to you.
 
Responsible for the treatment: WERFEN, with address at 59-61 Dickson Avenue, Artarmon, NSW 2064
 
Responsible for the data processing: WERFENLIFE, S.A., with address at Plaza Europa, 21-23 - 08908 L'Hospitalet de Llobregat (Barcelona). CIF: A08754111
 
Data Protection Officer: enquiries-au@wefen.com

Legal basis of the treatment: The treatment is necessary for the execution of a commercial contract of product and / or service; and your consent - with respect to commercial communications, supply of products and / or services, market research and improvement of our website.

Recipients or categories of recipients: Werfen companies and third parties to which WERFEN has entrusted the provision of services (hosting, training and communication services, organization of events). When legally or contractually required.
 
Term of conservation: While you are a user of our products and / or services and / or of our web page and whenever you have not opposed receiving commercial communications. Subsequently, the data will be maintained, duly blocked, for a period of 5 years.
 
Rights: You can exercise the rights of access, rectification or deletion, as well as request to limit your data processing, oppose it, request the portability of your data, or revoke the consent given by writing to enquiries-au@werfen.com
 
Likewise, the data subject is entitled to lodge a complaint with the OAIC https://www.oaic.gov.au/privacy/privacy-complaints/
 
The information you are sending us via this form will be used for the sole purpose of responding to your request and, therefore, this may be transferred to other Werfen companies or subsidiaries in other countries.
 
By clicking “I accept”, you agree that your data will be governed by our Data Protection Policy

* Mandatory field